Cardiol MAVERIC Phase III Enrollment Expansion
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The enrollment milestone and trial expansion modestly de-risk CardiolRx's regulatory path while pushing the key topline readout to mid-2027, a timing delay that tempers near-term catalysts. For a small-cap clinical-stage biotech, the news is mildly positive on execution but neutral-to-slightly-negative on timeline, with limited spillover to broader markets.
Cardiol Therapeutics Inc. announced on September 23, 2026 that its pivotal Phase III MAVERIC trial of CardiolRx for recurrent pericarditis reached its original 110-patient enrollment target ahead of end-of-September guidance. Following a blinded review showing fewer-than-expected pericarditis recurrences, the MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to preserve statistical power and enable a more robust efficacy assessment. Topline results are now anticipated in mid-2027, versus prior Q1 2027 guidance. CardiolRx has received Orphan Drug Designation from the U.S. United States — Food and Drug Administration for pericarditis. The company stated its existing capital is expected to fund MAVERIC completion, with cash runway into Q1 2028. Cardiol Therapeutics is listed on the Nasdaq and the Toronto Stock Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard